- Home
- CPAC vs LRMR Comparison
CPAC vs LRMR Comparison
Compare CPAC & LRMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CPAC
- LRMR
- Stock Information
- Founded
- CPAC 1949
- LRMR N/A
- Country
- CPAC Peru
- LRMR United States
- Employees
- CPAC N/A
- LRMR N/A
- Industry
- CPAC Building Materials
- LRMR Biotechnology: Pharmaceutical Preparations
- Sector
- CPAC Industrials
- LRMR Health Care
- Exchange
- CPAC Nasdaq
- LRMR Nasdaq
- Market Cap
- CPAC 475.3M
- LRMR 426.9M
- IPO Year
- CPAC 2012
- LRMR N/A
- Fundamental
- Price
- CPAC $5.77
- LRMR $3.19
- Analyst Decision
- CPAC Sell
- LRMR Strong Buy
- Analyst Count
- CPAC 1
- LRMR 9
- Target Price
- CPAC $6.00
- LRMR $19.44
- AVG Volume (30 Days)
- CPAC 5.1K
- LRMR 639.4K
- Earning Date
- CPAC 03-04-2025
- LRMR 03-13-2025
- Dividend Yield
- CPAC 8.69%
- LRMR N/A
- EPS Growth
- CPAC 17.75
- LRMR N/A
- EPS
- CPAC 0.12
- LRMR N/A
- Revenue
- CPAC $524,464,683.00
- LRMR N/A
- Revenue This Year
- CPAC N/A
- LRMR N/A
- Revenue Next Year
- CPAC N/A
- LRMR N/A
- P/E Ratio
- CPAC $9.19
- LRMR N/A
- Revenue Growth
- CPAC 1.44
- LRMR N/A
- 52 Week Low
- CPAC $5.10
- LRMR $3.01
- 52 Week High
- CPAC $6.65
- LRMR $12.91
- Technical
- Relative Strength Index (RSI)
- CPAC 49.77
- LRMR 37.56
- Support Level
- CPAC $5.70
- LRMR $3.06
- Resistance Level
- CPAC $6.00
- LRMR $3.52
- Average True Range (ATR)
- CPAC 0.15
- LRMR 0.22
- MACD
- CPAC -0.01
- LRMR 0.02
- Stochastic Oscillator
- CPAC 31.88
- LRMR 15.66
About CPAC Cementos Pacasmayo S.A.A. (Each representing five)
Cementos Pacasmayo SAA is a Peruvian cement company that primarily produces, distributes, and sells cement and cement-related materials, such as concrete blocks and ready-mix concrete. The company's products are primarily used in construction. It also produces and sells quicklime for use in mining operations. The company sells its products mainly in the northern part of Peru. It owns three cement production facilities. Its flagship Pacasmayo facility is located in the northwest region of Peru, while its new cement plant in Piura and smaller Rioja facility are located in the northeast region of Peru.
About LRMR Larimar Therapeutics Inc.
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using novel cell-penetrating peptide technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.